Article from info@onco-suisse: Rising Costs in Oncology

Spending on cancer care is rising and is increasingly becoming a focus of health policy discussions. The prices of new drugs and therapies are often viewed as key cost drivers. However, the situation is more complex: population growth, an aging population, and medical advances also contribute to rising costs.

Rising expenditures on medications and other treatments in oncology are increasingly becoming the focus of health policy discussions. This often gives the impression that the prices of new drugs, in particular, are the main drivers of costs. However, a more nuanced analysis reveals that, in addition to the costs of innovative therapies, other factors also play a significant role—including population growth and an aging population.

At the same time, medical progress should not be viewed solely from a cost perspective. The benefits that innovations bring to patients and to society are also crucial. In oncology, medical advances have played a major role in helping people live longer and enjoy a better quality of life. The improvements in everyday life that are immediately noticeable to patients and their families deserve special attention.

Today, more patients are achieving complete remission. At the same time, the number of people living with chronic cancer over the long term is rising. As a result, cancer is becoming a disease for an increasing number of people that must be managed and treated over an extended period of time.

This development poses new challenges for cancer care throughout the entire treatment journey. Therefore, innovative and sustainable care models are needed that take into account not only the treatment of the disease but also the long-term needs of patients.

The changes taking place in oncology require forward-thinking action. The necessary changes should therefore be shaped proactively—with the goal of enabling medical progress, improving quality of life, and, at the same time, ensuring sustainable and future-proof cancer care.